While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

Eli Lilly’s acquisition of in-vivo CAR-T company Colonia Therapeutics signals a deliberate strategy to bypass the crowded and still unproven allogeneic cell therapy space. By investing directly in technology that modifies T-cells inside the body, Lilly is betting it can leapfrog the current generation of cell therapies toward a more scalable platform.

Observing that allogeneic ('off-the-shelf') cell therapies have not yet achieved their expected impact, Kite Pharma is strategically investing in in vivo approaches. Through acquisitions and partnerships, they are focusing on technologies that edit cells directly within the body, which have shown promising 'autologous-like' results.

The in vivo CAR-T field is not a "winner-takes-all" market. A strategic split is emerging, reflected in Big Pharma M&A. Reversible, finite-exposure RNA-based therapies are preferred for autoimmune diseases due to safety, while more permanent lentiviral vectors are reserved for high-risk oncology indications.

The next frontier in cellular therapy is in-vivo CAR-T, where a gene for the CAR receptor is delivered into the patient (e.g., via mRNA lipid nanoparticles) to create CAR-T cells internally. This eliminates the complex and costly external manufacturing process, potentially creating an 'off-the-shelf' CAR-T therapy.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

The high capital cost of autologous CAR-T manufacturing creates a moat for incumbents like Legend. Consequently, future investment will likely flow towards next-generation platforms like in vivo CAR-T, which promises an "off-the-shelf" solution that eliminates complex external manufacturing and patient pre-conditioning.

The commercial challenges of Bluebird Bio's "single therapy for a single patient" model were a key catalyst for the industry's evolution. This reality pushed the field toward developing more economically viable and broadly applicable technologies, like in vivo CAR-T, that can reach more patients globally.